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Access to antiretroviral therapy (ART) is a global priority. However, the attrition across the
continuum of care for HIV-infected children between their HIV diagnosis and ART initiation
is not well known. We analyzed the time from enrollment into HIV care to ART initiation in
HIV-infected children within the International Epidemiology Databases to Evaluate AIDS
(IeDEA) Global Cohort Consortium.
Methods and findings
We included 135,479 HIV-1-infected children, aged 0–19 years and ART-naïve at enroll-
ment, between 1 January 2004 and 31 December 2015, in IeDEA cohorts from Central
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Africa (3 countries; n = 4,948), East Africa (3 countries; n = 22,827), West Africa (7 coun-
tries; n = 7,372), Southern Africa (6 countries; n = 93,799), Asia-Pacific (6 countries; n =
4,045), and Latin America (7 countries; n = 2,488). Follow-up in these cohorts is typically
every 3–6 months. We described time to ART initiation and missed opportunities (death or
loss to follow-up [LTFU]: last clinical visit >6 months) since baseline (the date of HIV diagno-
sis or, if unavailable, date of enrollment). Cumulative incidence functions (CIFs) for and
determinants of ART initiation were computed, with death and LTFU as competing risks.
Among the 135,479 children included, 99,404 (73.4%) initiated ART, 1.9% died, 1.4% were
transferred out, and 20.4% were lost to follow-up before ART initiation. The 24-month CIF
for ART initiation was 68.2% (95% CI: 67.9%–68.4%); it was lower in sub-Saharan Africa—
ranging from 49.8% (95% CI: 48.4%–51.2%) in Central Africa to 72.5% (95% CI: 71.5%–
73.5%) in West Africa—compared to Latin America (71.0%, 95% CI: 69.1%–72.7%) and the
Asia-Pacific (78.3%, 95% CI: 76.9%–79.6%). Adolescents aged 15–19 years and infants <1
year had the lowest cumulative incidence of ART initiation compared to other ages: 62.2%
(95% CI: 61.6%–62.8%) and 66.4% (95% CI: 65.7%–67.0%), respectively. Overall, 49.1%
were ART-eligible per local guidelines at baseline, of whom 80.6% initiated ART. The follow-
ing children had lower cumulative incidence of ART initiation: female children (p < 0.01);
those aged <1 year, 2–4 years, 5–9 years, and 15–19 years (versus those aged 10–14
years, p < 0.01); those who became eligible during follow-up (versus eligible at enrollment,
p < 0.01); and those receiving care in low-income or lower-middle-income countries (p <
0.01). The main limitations of our study include left truncation and survivor bias, caused by
deaths of children prior to enrollment, and use of enrollment date as a proxy for missing data
on date of HIV diagnosis, which could have led to underestimation of the time between HIV
diagnosis and ART initiation.
Conclusions
In this study, 68% of HIV-infected children initiated ART by 24 months. However, there was
a substantial risk of LTFU before ART initiation, which may also represent undocumented
mortality. In 2015, many obstacles to ART initiation remained, with substantial inequities.
More effective and targeted interventions to improve access are needed to reach the target
of treating 90% of HIV-infected children with ART.
Author summary
Why was this study done?
• Access to antiretroviral therapy (ART) has been highlighted as an urgent global priority
area by a diverse range of stakeholders, including the World Health Organization, the
Joint United Nations Programme on HIV/AIDS (UNAIDS), and, more specifically for
children, the United Nations Children’s Fund.
• In 2014, UNAIDS set the ambitious 90-90-90 targets that, by 2020, 90% of people living
with HIV should know their HIV status, 90% of HIV-infected people who know their
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HIV status should receive antiretroviral treatment, and 90% of people on treatment
should be virologically suppressed.
• In low/middle-income countries, the attrition across the continuum of care for HIV-
infected children between their HIV diagnosis, linkage to care, and ART initiation is
not well characterized.
What did the researchers do and find?
• We used the International Epidemiological Databases to Evaluate AIDS (IeDEA), bring-
ing together data from 6 different regions worldwide (in Asia-Pacific, sub-Saharan
Africa, and Latin America), including the regions most affected by the HIV epidemic, to
describe access to pediatric ART since the scaling up of ART.
• We described the cumulative incidence of and time to ART initiation in HIV-infected
children in care between 2004 and 2015 (n = 135,479) according to region, sex, age, and
eligibility criteria at baseline, since enrollment in care or HIV diagnosis, when this was
available.
• The global probability for initiating ART within 2 years in care was 68%; 20% of the chil-
dren were lost to follow-up, and 2% died before initiating treatment.
• ART initiation rates were lower in sub-Saharan Africa compared to the other regions,
and children aged <1 year and those aged 15–19 years were the least likely to initiate
treatment.
• Overall, 49% of the children were eligible for ART at baseline, and 81% of these children
initiated treatment.
What do these findings mean?
• In many low- and middle-income countries, obstacles to ART initiation for children
remained, with substantial inequities, in 2015.
• More effective and targeted interventions to improve access are needed to reach the tar-
get of treating 90% of children with ART.
• With adoption of universal treatment recommendations since 2015, it will be crucial to
further monitor progress and identify gaps in ART coverage to achieve the 90-90-90 tar-
gets for children and adolescents.
Introduction
By the end of 2016, the Joint United Nations Programme on HIV/AIDS (UNAIDS) estimated
that 2.1 million children aged<15 years were living with HIV worldwide [1]. Despite effective
interventions for the prevention of mother-to-child transmission, the pediatric epidemic per-
sists, and an estimated 160,000 children were newly infected with HIV in 2016 [1].
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Furthermore, the incidence of HIV remains alarmingly high in adolescents and young people
aged 15–24 years. According to UNAIDS, 37% of new HIV infections occurring in sub-Saha-
ran African adults in 2016 were among this population [1].
In the absence of timely antiretroviral therapy (ART), mortality in HIV-infected children
reaches 52% by the age of 2 years [2]. Systematic early ART initiation in infants <3 months of
age has proven an effective intervention in reducing early infant mortality, and the World
Health Organization (WHO) has recommended ART in all HIV-infected children aged<2
years since 2010; in 2013, the recommendation to initiate ART regardless of clinical stage or
CD4 count was extended to children <5 years [3–5]. In 2015, guidelines were revised to rec-
ommend ART initiation regardless of age, clinical, or immunological criteria [6]. However, in
2015, 49% of children aged<15 years who were eligible for ART based on previous guidelines
were still not receiving treatment worldwide [7]. Many of those children who did not initiate
ART either had no access to treatment or had unknown HIV status, mainly through lack of
access to early HIV diagnosis.
In 2014, UNAIDS set the ambitious targets that, by 2020, 90% of people living with HIV
should know their HIV status, 90% of people who know their HIV status should receive treat-
ment, and 90% of people on treatment should be virologically suppressed [8]. However, in
low-income and middle-income countries, attrition across the continuum of care for HIV-
infected children between their HIV diagnosis and ART initiation is not well known. The
period between diagnosis of HIV infection and ART initiation, which includes periods from
testing to linkage to care and then from inclusion in care to ART initiation, is known as the
pre-ART cascade. Throughout the pre-ART period, children are at risk for attrition due to
death and loss to follow-up (LTFU). A better understanding of the attrition of children across
the pre-ART cascade is crucial to reach the 90-90-90 targets, particularly for the second target,
to initiate ART in 90% of HIV-infected children identified, assuming that 90% have been iden-
tified among those HIV infected.
In 2006, the US National Institutes of Health launched the International Epidemiology
Databases to Evaluate AIDS (IeDEA) to describe trends in HIV epidemiology in the context of
ART access across regions of the world (https://www.iedea.org/). Clinics from 7 international
regional data centers contribute both retrospective cohort data, prior to 2006, and prospective
data since, on care and treatment of HIV to evaluate the outcomes of people living with HIV/
AIDS. To better understand the continuum of care from HIV diagnosis to ART initiation in
HIV-infected children and in collaboration with WHO, we performed a multiregional analysis
of the pre-ART retention cascade of HIV-infected children from HIV diagnosis to ART initia-
tion within IeDEA from 2004 to 2015.
Methods
Study design and population
This multiregional analysis was prespecified, except for the sensitivity analysis, in an approved
concept plan available in the Supporting Information (S1 Concept Plan). We pooled individual
patient data from 6 pediatric cohorts of IeDEA and included clinical care sites from Asia-
Pacific, West Africa, East Africa, Central Africa, Southern Africa, and Latin America. We
included all HIV-infected children aged 0–19 years at enrollment into any IeDEA-affiliated
pediatric care program who were ART-naïve at enrollment (except for exposure to perinatal
prevention of mother-to-child transmission prophylaxis) between 1 January 2004 (corre-
sponding to the beginning of the era of ART access in low-income countries) and 31 Decem-
ber 2015.
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Although each clinic within IeDEA has its own protocol for routine follow-up, HIV-
infected children who have not yet been initiated on ART are typically seen at least every 6
months.
The data abstracted for this analysis were from routine care and included region, country,
site, patient demographics (sex, date of birth, date of HIV diagnosis if available, and date of
enrollment in care), clinical WHO/CDC staging at enrollment and ART initiation, laboratory
values and dates (CD4 cell count, CD4 percent), cotrimoxazole start date, date of ART initia-
tion, ART regimen, and date of death, LTFU, or transfer out.
Outcomes and key variable definitions
The outcomes of interest were (1) time to ART initiation and (2) missed opportunities for
ART initiation, defined as either death or LTFU (last clinical visit>6 months before database
closure and whereabouts unknown). Baseline was defined as the date of diagnosis, whether
this occurred before or after enrollment in the HIV care program; when this date was unavail-
able, which was frequent in these contexts, we defined baseline as the date of enrollment in the
HIV care program. The follow-up period was defined as the time between baseline and the
date of ART initiation, death, LTFU, transfer out, or database closure (31 December 2015),
whichever came first.
Statistical analysis
We assessed the proportion of children initiating ART and the proportion with missed oppor-
tunities for ART initiation (death or LTFU) within the first 24 months after enrollment. This
conservative time-point was prespecified to provide a reference analysis in scaling up HIV
diagnosis and ART initiation before the treat-all era from 2015 onwards. Baseline categorical
data are presented as frequency (percent), and continuous data are presented as median (inter-
quartile range [IQR]). Continuous variables were compared using the Kruskal–Wallis test, and
categorical variables using the chi-squared or Fisher’s test. Time to ART initiation was esti-
mated using cumulative incidence functions (CIFs): mortality and LTFU were considered
competing events to ART initiation [9], while those transferred out were right-censored, with
the assumption that they remained in HIV care and had similar outcomes as patients still in
observation.
To better understand the different patterns of ART initiation, taking into account the evolv-
ing WHO eligibility criteria for ART initiation between 2004 and 2015 [4,5,10,11], we
described the percentage of children eligible for ART initiation at baseline and during follow-
up according to WHO guidelines, combining clinical criteria (WHO stage 3 or 4 or AIDS,
though these data were unavailable in the Southern Africa database) and severe immunodefi-
ciency for age (CD4 25% if age< 5 years or CD4 350 cells/μl if age 5 years) if enroll-
ment in care occurred prior to 1 April 2008; additional age criteria were added if enrolled later
(age <1 year between 1 April 2008 and 30 June 2010, age< 2 years between 1 July 2010 and 31
May 2013, and age< 5 years on or after 1 June 2013).
Correlates of ART initiation were described in a multivariate competing risks analysis using
the Fine and Gray proportional sub-distribution hazards regression model, where time of ori-
gin was baseline [12]. Explanatory variables included sex, age at baseline, region, country
income as defined by the World Bank (http://data.worldbank.org/about/country-and-lending-
groups), period of enrollment based on the changing WHO treatment guidelines (before April
2008, April 2008–June 2010, July 2010–May 2013, and after May 2013), and clinical/immuno-
logical criteria for ART eligibility at baseline and during follow-up. Model fit was checked
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graphically, plotting the Schoenfeld-type residuals against time for each of the covariates
included in the model; we used the %pshreg SAS macro for this [13,14].
There was a high degree of variability of data collection practices across the HIV programs
included in IeDEA, and some centers followed up only children who were eligible at baseline
to be initiated on ART. It is likely that those programs only recorded data if children initiated
ART or were intended to initiate ART before being followed up in a decentralized center. Con-
sequently, incidence of ART initiation among all children in HIV care may be overestimated
by these programs. For this reason, we performed an un-prespecified sensitivity analysis
excluding the clinics where the ART coverage was >95% of all the patients followed up.
Analyses were conducted using the package cmprsk in R statistical software version 2.11.1
(R Foundation for Statistical Computing, Vienna, Austria). The adjusted sub-distribution haz-
ard ratios (asHRs) were reported with their 95% confidence intervals (CIs). A p-value less than
0.05 was considered statistically significant.
Ethics
Each participating IeDEA region formally agreed to contribute pediatric data, with local insti-
tutional review board and US National Institutes of Health approvals to contribute to multire-
gional analyses.
Results
Baseline characteristics and follow-up
Overall, 180,419 children and adolescents were included in the IeDEA, of whom 120,413 were
<15 years; this represents about 6% of all children living with HIV worldwide according to
UNAIDS estimates. Of these, 3,262 (1.9%) were excluded due to incoherent data, 35,439
(19.6%) because they were>19 years of age, 2,194 (1.2%) because they were not ART-naïve at
baseline—these children most likely entered in IeDEA active files transferring from other clin-
ics while they were already on ART but without a date of ART initiation—and 4,045 (2.2%)
because the date of enrollment in the site was before 2004 or after 2015, leaving 135,479
(75.1%) who met the inclusion criteria and were included in the study; 69.2% were from
Southern Africa. Among all children included, 27,831 (20.5%) had a documented date of HIV
diagnosis at or after enrollment (for those HIV-exposed) and 18,035 (13.3%) had a docu-
mented date of HIV diagnosis prior to enrollment; for the remaining 89,613 (66.1%), the date
of enrollment was used as baseline (Fig 1).
Table 1 describes the patients’ characteristics at baseline. Children were enrolled at a late
age, 6 years in median (IQR: 2–12), but the median age varied by region, ranging from 4 years
in West Africa (IQR: 2–9) and Asia-Pacific (IQR: 2–7) to 8 years in Latin America (IQR:
2–16). This variation was mainly driven by the proportion of adolescents enrolled in the HIV
care programs in each region. Overall, 32.1% of children were adolescents (10 years) at base-
line. This varied across regions, with Asia-Pacific having the smallest proportion (9.9%), and
Latin America the largest (43.2%). Children aged 5–9 years were the most commonly repre-
sented group overall (23.5%). Median CD4 percentage at baseline was 17% (IQR: 10%–25%)
overall: 12% in Asia-Pacific, 15% in West Africa, 16% in Central Africa and Latin America,
17% in Southern Africa, and 19% in East Africa (p< 0.01). At the time of their enrollment,
49.1% of children were known to be eligible for ART initiation according to WHO recommen-
dations. This percentage ranged from 43.0% in Central Africa to 74.5% in the Asia-Pacific
region. Forty-eight percent of children could not be classified for ART eligibility at baseline
due to missing clinical and/or immunological data.
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Fig 1. Flow diagram of the inclusion criteria of the 135,479 HIV-infected children aged 0–19 years enrolled in the IeDEA
Global Cohort Consortium from 2004 to 2015.
https://doi.org/10.1371/journal.pmed.1002565.g001
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Table 1. Baseline (HIV diagnosis or, if unavailable, enrollment in care) characteristics of the 135,479 HIV-infected children included, by region, in the IeDEA
Global Cohort Consortium, 2004–2015.
Characteristic Region Total p-Value
Asia-Pacific Central Africa Latin America East Africa Southern Africa West Africa
N 4,045 4,948 2,488 22,827 93,799 7,372 135,479
Sex, n (%) <0.01
Males 2,082 (51.5) 2,222 (44.9) 1,106 (44.5) 9,642 (42.2) 40,486 (43.2) 3,414 (46.3) 58,952 (43.5)
Females 1,963 (48.5) 2,726 (55.1) 1,382 (55.5) 13,185 (57.8) 53,154 (56.7) 3,480 (47.2) 75,890 (56.0)
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 159 (0.2) 478 (6.5) 637 (0.5)
Median age at baseline (years) (IQR) 4 (2–7) 7 (3–12) 8 (2–16) 6 (3–12) 6 (2–12) 4 (2–9) 6 (2–12) <0.01
Age at baseline, n (%) <0.01
0–11 months 653 (16.1) 570 (11.5) 425 (17.1) 2,449 (10.7) 14,859 (15.8) 1,061 (14.4) 20,017 (14.8)
12–23 months 508 (12.6) 377 (7.6) 211 (8.5) 2,014 (8.8) 11,001 (11.7) 1,114 (15.1) 15,225 (11.2)
2–4 years 1,233 (30.5) 912 (18.4) 354 (14.2) 5,383 (23.6) 15,307 (16.3) 1,769 (24.0) 24,958 (18.4)
5–9 years 1,249 (30.9) 1,345 (27.2) 423 (17.0) 5,798 (25.4) 21,073 (22.5) 1,904 (25.8) 31,792 (23.5)
10–14 years 377 (9.3) 966 (19.5) 404 (16.2) 3,312 (14.5) 15,030 (16.0) 941 (12.8) 21,030 (15.5)
15–19 years 25 (0.6) 778 (15.7) 671 (27.0) 3,871 (17.0) 16,529 (17.6) 583 (7.9) 22,457 (16.6)
Country income, n (%) <0.01$
Low income 593 (14.7) 4,948 (100.0) 1,704 (68.5) 22,827 (100.0) 12,671 (13.5) 2,136 (29.0) 44,879 (33.1)
Lower middle income 2,235 (55.3) 0 (0.0) 201 (8.1) 0 (0.0) 46,275 (49.3) 5,236 (71.0) 53,947 (39.8)
Upper middle income 1,217 (30.1) 0 (0.0) 563 (22.6) 0 (0.0) 34,853 (37.2) 0 (0.0) 36,633 (27.0)
High income 0 (0.0) 0 (0.0) 20 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 20 (0.01)
Year of enrollment, n (%) <0.01
<April 2008 2,139 (52.9) 2,184 (44.1) 1,006 (40.4) 8,003 (35.1) 26,338 (28.1) 3,045 (41.3) 42,715 (31.5)
April 2008–June 2010 1,009 (24.9) 1,116 (22.6) 427 (17.2) 6,437 (28.2) 23,141 (24.7) 1,429 (19.4) 33,559 (24.8)
July 2010–May 2013 701 (17.3) 1,200 (24.3) 696 (28.0) 6,590 (28.9) 27,065 (28.9) 1,729 (23.5) 37,981 (28.0)
June 2013 196 (4.8) 448 (9.1) 359 (14.4) 1,797 (7.9) 17,255 (18.4) 1,169 (15.9) 21,224 (15.7)
Access to care, n (%) <0.01
Enrolled following an HIV diagnosis 2,360 (58.3) 1,519 (30.7) 988 (39.7) 2,015 (8.8) 9,565 (10.2) 1,588 (21.5) 18,035 (13.3)
Diagnosis at time of enrollment 918 (22.7) 1,280 (25.9) 1,171 (47.1) 9,609 (42.1) 9,459 (10.1) 552 (7.5) 22,989 (17.0)
Diagnosis after enrollment 653 (16.1) 144 (2.9) 329 (13.2) 2,018 (8.8) 1,205 (1.3) 493 (6.7) 4,842 (3.6)
No date of confirmed HIV diagnosis
available
114 (2.8) 2,005 (40.5) 0 (0.0) 9,185 (40.2) 73,570 (78.4) 4,739 (64.3) 89,613 (66.1)
WHO/CDC clinical stage at baseline,
n (%)
<0.01
Stage 1/2 or CDC stage A/B 1,292 (31.9) 1,470 (29.7) 428 (17.2) 8,158 (35.7) 0 (0.0) 1,968 (26.7) 13,316 (9.8)
Stage 3/4 or AIDS 1,925 (47.6) 1,103 (22.3) 190 (7.6) 2,137 (9.4) 0 (0.0) 2,621 (35.6) 7,976 (5.9)
Unknown 828 (20.5) 2,375 (48.0) 1,870 (75.2) 12,532 (54.9) 93,799 (100.0) 2,783 (37.8) 114,187 (84.3)
Severe immunodeficiency for age at
baseline, n (%)
<0.01
Yes 2,177 (53.8) 948 (19.2) 787 (31.6) 6,610 (29.0) 32,314 (34.5) 2,996 (40.6) 45,832 (33.8)
No 772 (19.1) 954 (19.3) 555 (22.3) 5,855 (25.6) 19,903 (21.2) 1,320 (17.9) 29,359 (21.7)
Missing 1,096 (27.1) 3,046 (61.6) 1,146 (46.1) 10,362 (45.4) 41,582 (44.3) 3,056 (41.5) 60,288 (44.5)
Clinical£ or immunological ART
eligibility at baseline, n (%)
<0.01
Yes 2,864 (70.8) 1,676 (33.9) 893 (35.9) 8,082 (35.4) 32,314 (34.5) 4,416 (59.9) 50,245 (37.1)
No 370 (9.1) 462 (9.3) 174 (7.0) 2,413 (10.6) 0 (0.0) 430 (5.8) 3,849 (2.8)
Missing 811 (20.0) 2,810 (56.8) 1,421 (57.1) 12,332 (54.0) 61,485 (65.5) 2,526 (34.3) 81,385 (60.1)
Eligible for ART according to WHO
recommendations& at baseline, n (%)
<0.01
Yes 3,014 (74.5) 2,140 (43.2) 1,222 (49.1) 10,479 (45.9) 44,632 (47.6) 4,995 (67.8) 66,482 (49.1)
No 300 (7.4) 459 (9.3) 156 (6.3) 2,379 (10.4) 0 (0.0) 380 (5.2) 3,674 (2.7)
(Continued)
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Access to care varied greatly over regions. Overall, 31.5% of children were enrolled prior to
April 2008; this represented 52.9% of the cohort in the Asia-Pacific region but only 28.1% in
Southern Africa. Of all children in the database, 66.1% did not have a date of confirmed HIV
diagnosis in the database: in Latin America and Asia-Pacific, a smaller proportion of children
lacked HIV diagnosis date (0.0% and 2.8%, respectively), but in Southern Africa this propor-
tion was 78.4%. Among those with a date of confirmed HIV diagnosis, 39.3% of children were
diagnosed prior to enrollment in IeDEA, ranging from 14.8% in East Africa to 60.3% in West
Africa (p< 0.001; Table 1); the overall median time to enrollment in care since HIV diagnosis
among these children was 1 month (IQR: 0–7).
Incidence of ART initiation
Among the 135,479 children included in the study, 99,404 (73.4%) initiated ART. The median
time to ART initiation was 1 month (IQR: 0–6 months); 1.9% died, 1.4% were transferred out,
and 20.4% were lost to follow-up before any ART initiation (Table 2). Time to ART initiation
varied according to the timing of diagnosis. Among those diagnosed prior to enrollment in
care, the median time to ART since diagnosis was 4 months (IQR: 1–19); among those diag-
nosed after enrollment in care, median time to ART was 3 months (IQR: 1–10). Among those
with no documented date of HIV diagnosis, median time from enrollment to ART was 1
month (IQR: 0–5). Finally, among those enrolled at time of diagnosis, the median time from
baseline to ART was 2 months (IQR: 0–8).
After 1 month of pre-ART follow-up, the CIF for ART initiation in all HIV-infected chil-
dren was estimated to be 35.7% (95% CI: 35.4%–35.9%) while the CIF for missed opportunities
(death or LTFU) was 10.7% (95% CI: 10.5%–10.9%). By 24 months of pre-ART follow-up, the
CIF for ART initiation had reached 68.2% (95% CI: 67.9%–68.4%), and the 24-month cumula-
tive incidence for missed opportunities was 19.3% (95% CI: 19.1%–19.5%). Fig 2A presents
the 24-month CIF for time to ART initiation since baseline by region. It was 71.0% (95% CI:
69.1%–72.7%) and 78.3% (95% CI: 76.9%–79.6%) for Latin America and the Asia-Pacific,
respectively. In sub-Saharan Africa, the 24-month CIF for ART initiation was significantly
Table 1. (Continued)
Characteristic Region Total p-Value
Asia-Pacific Central Africa Latin America East Africa Southern Africa West Africa
Missing 731 (18.1) 2,349 (47.5) 1,110 (44.6) 9,969 (43.7) 49,167 (52.4) 1,997 (27.1) 65,323 (48.2)
Measure of CD4 cell count available, n
(%)
2,976 (73.6) 1,562 (31.6) 1,658 (66.6) 13,506 (59.2) 54,353 (57.9) 4,839 (65.6) 78,894 (58.2)
Median CD4 cell count (cells/μl) (IQR) 353 (63–830) 427 (217–668) 395 (182–718) 484 (232–820) 418 (207–758) 453 (163–831) 430 (203–773) <0.01
Measure of CD4 percentage available, n
(%)
2,917 (72.1) 432 (8.7) 526 (21.1) 9,479 (41.5) 42,534 (45.3) 3,548 (48.1) 59,436 (43.9)
Median CD4 percentage (IQR) 12 (4–22) 16 (11–23) 16 (8–26) 19 (11–27) 17 (11–25) 15 (7–22) 17 (10–25) <0.01
Males versus others.
$Low/lower middle/unknown versus upper middle/high.
Severe immunodeficiency for age: CD4 25% if age < 5 years or CD4 350 cells/μl if age 5 years.
£Clinical stage WHO 3 or 4 or AIDS.
&Baseline before 1 April 2008: clinical or immunological eligibility; baseline 1 April 2008–30 June 2010: clinical or immunological eligibility or children <1 year;
baseline 1 July 2010–31 May 2013: clinical or immunological eligibility or children <2 years; baseline on or after 1 June 2013: clinical or immunological eligibility or
children <5 years.
CDC, Centers for Disease Control and Prevention.
https://doi.org/10.1371/journal.pmed.1002565.t001
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lower, ranging from 49.8% (95% CI: 48.4%–51.2%) in Central Africa to 60.9% (95% CI:
60.3%–61.6%) in East Africa, 70.1% (95% CI: 69.8%–70.4%) in Southern Africa, and 72.5%
(95% CI: 71.5%–73.5%) in West Africa. We also noted that results differed by age at baseline:
children and adolescents aged 15–19 years and those aged<1 year at baseline had the lowest
ART initiation rates compared to other ages, with a 24-month CIF of 62.2% (95% CI: 61.6%–
62.8%) and 66.4% (95% CI: 65.7%–67.0%), respectively (Fig 2B).
Fig 2C presents CIFs for ART initiation according to ART eligibility at baseline. Among
children eligible at baseline, the 24-month CIF was 78.6% (95% CI: 78.3%–78.9%) compared
to 56.4% (95% CI: 55.1%–57.7%) among those known not to be eligible at baseline who
became eligible during follow-up. We also note that the CIF for ART initiation reached 39.4%
(95% CI: 37.6%–41.1%) at 24 months among children who did not meet ART eligibility crite-
ria. Among those with unknown eligibility criteria at baseline, the 24-month CIF for ART ini-
tiation was 58.7% (95% CI: 58.3%–59.1%) (S3 Fig).
ART initiation according to ART eligibility
To better understand the patterns of ART initiation, we present the ART eligibility for the
overall population (Fig 3). Of the 135,479 children included in the analysis, 66,482 (49.1%)
were known to be eligible for ART initiation according to WHO criteria at baseline, of whom
53,616 (80.6%) initiated ART. Among the 3,674 (2.7%) not eligible for ART at baseline, 5
(0.1%) became eligible during follow-up, of whom all initiated ART. Among the 65,323
(48.2%) who were not classified for ART eligibility at baseline due to missing clinical and/or
immunological data, 5,345 (8.2%) became eligible, of whom 4,275 (80.0%) initiated ART, and
692 (1%) did not meet eligibility criteria during follow-up, of whom 398 (57%) initiated ART.
Overall, 13,936 (19.4%) children known to be eligible for ART initiation, either at baseline or
during follow-up, never accessed treatment over the first 24 months of follow-up. These
missed opportunities for ART initiation highlight a substantial proportion of unmet needs.
In 2015, no region had yet reached the UNAIDS target of 90% of those diagnosed with HIV
infection on ART, though the Asia-Pacific, Latin America, and Southern and West Africa
Table 2. Outcomes among the 135,479 pre-ART children in the IeDEA Global Cohort Consortium, 2004–2015.
Variable or outcome Region Total p-Value
Asia-Pacific Central Africa Latin America East Africa Southern Africa West Africa
N 4,045 4,948 2,488 22,827 93,799 7,372 135,479
Death before ART initiation, n (%) 76 (1.9) 101 (2.0) 20 (0.8) 730 (3.2) 1,397 (1.5) 218 (3.0) 2,542 (1.9) <0.01
Transferred out before ART initiation,
n (%)
222 (5.5) 194 (3.9) 10 (0.4) 322 (1.4) 939 (1.0) 220 (3.0) 1,907 (1.4) <0.01
Loss to follow-up (>6 months) before ART
initiation, n (%)
94 (2.3) 1,353 (27.3) 197 (7.9) 5,116 (22.4) 19,805 (21.1) 1,047 (14.2) 27,612 (20.4) <0.01
Censored due to end of study, n (%) 102 (2.5) 178 (3.6) 56 (2.3) 1,062 (4.7) 2,458 (2.6) 158 (2.1) 4,014 (3.0)
ART initiation, n (%) 3,551 (87.8) 3,122 (63.1) 2,205 (88.6) 15,597 (68.3) 69,200 (73.8) 5,729 (77.7) 99,404 (73.4) <0.01
On ART at baseline, n (%) 132 (3.7) 157 (5.0) 74 (3.4) 1,562 (10.0) 18,964 (27.4) 913 (15.9) 21,802 (21.9) <0.01
Median duration between baseline and
ART initiation or last contact (months)
(IQR)
2 (1–12) 5 (1–26) 4 (1–24) 3 (1–11) 1 (0–5) 1 (0–6) 1 (0–7) <0.01
Median duration between ART eligibility
and ART initiation/last contact (months)
(IQR)
2 (1–10) 4 (1–23) 4 (1–22) 3 (1–11) 1 (0–5) 1 (0–5) 1 (0–6) <0.01
Closure date 30 May 2015 21 Apr 2016 30 May 2016 31 Dec 2014 29 Jan 2016 17 May 2016
https://doi.org/10.1371/journal.pmed.1002565.t002
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IeDEA regions had percentages of ART initiation close to 80% (Fig 4). Central and East Africa
had the lowest coverage (49% and 59%, respectively). A substantial proportion of eligible chil-
dren did not initiate ART during the study period, ranging from 9% in Latin America to 15%
in West Africa and 16% in Central Africa.
Fig 3. ART initiation according to ART eligibility at baseline and during follow-up among the 135,479 HIV-
infected children in the IeDEA Global Cohort Consortium, 2004–2015.
https://doi.org/10.1371/journal.pmed.1002565.g003
Fig 2. Cumulative incidence functions for ART initiation by region, age at baseline, and timing of eligibility for ART, among the 135,479 HIV-infected pre-ART
children within the IeDEA Global Cohort Consortium, 2004–2015. By region (A), age at baseline (B), and timing of eligibility for ART (C).
https://doi.org/10.1371/journal.pmed.1002565.g002
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Correlates of ART initiation
In the multivariate Fine and Gray analysis, sex, region, age at baseline, period of enrollment,
country income, and clinical or immunological eligibility were all associated with ART initia-
tion (Table 3). Adjusted for the above variables, females were less likely to initiate ART com-
pared to their male counterparts (asHR: 0.94, 95% CI: 0.92–0.95). Compared to Latin America,
3 sub-Saharan African regions were less likely to initiate ART, with asHRs ranging from 0.69
(95% CI: 0.66–0.72) in Central Africa and 0.80 (95% CI: 0.77–0.83) in East Africa to 0.93 (95%
CI: 0.90–0.97) in Southern Africa. Children from the Asia-Pacific and West Africa regions had
similar hazard of treatment initiation compared to those from Latin America (asHR: 1.01, 95%
CI: 0.97–1.05, and asHR: 1.02, 95% CI: 0.97–1.06, respectively). Adolescents aged 10–14 years
at baseline were the most likely to initiate ART compared to all other age groups. Infants aged
<1 year and adolescents aged15 years were less likely to initiate ART compared to those 10–
14 years old (asHR: 0.83, 95% CI: 0.81–0.85, and asHR: 0.73, 95% CI: 0.71–0.75, respectively).
Children enrolled prior to June 2013 were also less likely to initiate ART than those enrolled
more recently, adjusted for other variables, and we noted a tendency towards lower likelihood
of initiating ART in earlier enrollment periods (asHR: 0.78, 95% CI: 0.76–0.80, for those with
enrollment in July 2010–May 2013; asHR: 0.63,95% CI: 0.61–0.64, for those enrolled in the
period April 2008–June 2010; and asHR: 0.57, 95% CI: 0.55–0.58, for those enrolled prior to
April 2008) compared to those enrolled in or beyond June 2013. ART initiation was also asso-
ciated with country income: children from countries of low or lower middle income were less
likely to initiate ART compared to those from upper-middle- and high-income settings (asHR:
0.76, 95% CI: 0.75–0.78). Finally, we found that children who became eligible for ART initia-
tion (per clinical and/or immunological criteria, but not on age criteria—that was a separate
variable) during follow-up were less likely to initiate ART compared to those who were eligible
at baseline (asHR: 0.61, 95% CI: 0.60–0.63).
Sensitivity analysis
Overall, 112,134 children were followed up in clinics where ART coverage was95%. Results are
presented in the Supporting Information (S2 and S3 Figs; S1 Table). Among these children, the
Fig 4. ART initiation after 24 months of follow-up according to eligibility at last contact, by region, among the
135,479 HIV-infected children (including those lost to follow-up or deceased prior to ART initiation) in the
IeDEA Global Cohort Consortium, 2004–2015.
https://doi.org/10.1371/journal.pmed.1002565.g004
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24-month CIF for ART initiation was estimated to be much lower than in the whole population,
at 62.9% (95% CI: 62.6%–63.2%), and the 24-month probability for missed opportunities for ART
was higher, at 23.3% (95% CI: 23.1%–23.6%), than in the whole population (S2 Fig). The children
from Asia-Pacific had the highest ART initiation rates, reaching 73.1% (95% CI: 71.4%–74.8%),
compared to all others, including those from sub-Saharan Africa, with 49.8% (95% CI: 48.4%–
51.2%) in Central Africa, 60.2% (95% CI: 58.8%–61.7%) in West Africa, 60.9% (95% CI: 58.8%–
61.7%) in East Africa, and 60.2% (95% CI: 58.8%–61.7%) in Southern Africa (S3 Fig). In the multi-
variate Fine and Gray competing risk analysis, we did not observe significant changes in correlates
Table 3. Factors associated with ART initiation during pre-ART follow-up in HIV-infected children (n = 135,479) in the IeDEA Global Cohort Consortium, 2004–
2015.
Characteristic Univariate analysis Full model
sHR 95% CI p-Value asHR 95% CI p-Value
Sex <0.01 <0.01
Males 1 — 1 —
Females 0.90 0.89–0.91 0.94 0.92–0.95
Missing 0.73 0.65–0.82 0.58 0.51–0.65
Region <0.01 <0.01
Latin America 1 — 1 —
Asia-Pacific 1.14 1.10–1.18 1.01 0.97–1.05
Central Africa 0.61 0.59–0.64 0.69 0.66–0.72
East Africa 0.73 0.70–0.75 0.80 0.77–0.83
Southern Africa 0.99 0.96–1.02 0.93 0.90–0.97
West Africa 1.05 1.01–1.09 1.02 0.97–1.06
Age at baseline <0.01 <0.01
0–11 months 0.79 0.77–0.80 0.83 0.81–0.85
12–23 months 0.84 0.82–0.86 0.86 0.84–0.88
2–4 years 0.84 0.82–0.86 0.88 0.86–0.90
5–9 years 0.89 0.87–0.91 0.97 0.95–0.98
10–14 years 1 — 1 —
15–19 years 0.74 0.72–0.75 0.73 0.71–0.75
Period of enrollment <0.01 <0.01
<April 2008 0.64 0.63–0.65 0.57 0.55–0.58
April 2008–June 2010 0.67 0.66–0.69 0.63 0.61–0.64
July 2010–May 2013 0.80 0.78–0.82 0.78 0.76–0.80
June 2013 1 — 1 —
Country income <0.01 <0.01
Upper middle/high 1 — 1 —
Low/lower middle 0.73 0.72–0.74 0.76 0.75–0.78
Clinical or immunological eligibility <0.01 <0.01
At baseline 1 — 1 —
During follow-up 0.56 0.55–0.58 0.61 0.60–0.63
Never 0.40 0.39–0.42 0.47 0.45–0.48
Missing 0.63 0.62–0.64 0.61 0.60–0.62
Reference groups were chosen based on those with the highest likelihood for ART initiation.
WHO clinical stage 3/4 or AIDS.
Severe immunodeficiency for age: CD4 25% if age < 5 years or CD4 350 cells/μl if age 5 years.
asHR, adjusted sub-distribution hazard ratio; sHR, sub-distribution hazard ratio.
https://doi.org/10.1371/journal.pmed.1002565.t003
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of ART initiation in this population, except for the effect of region, with the lowest asHR for ART
initiation in sub-Saharan Africa compared to Latin America, ranging from 0.60 in Central Africa
(95% CI: 0.57–0.63) and West Africa (95% CI: 0.57–0.63) and 0.70 in East Africa (95% CI: 0.67–
0.73) to 0.80 in Southern Africa (95% CI: 0.77–0.83) (S1 Table).
Discussion
This pooled analysis from the IeDEA Global Cohort Consortium documents time to ART ini-
tiation since enrollment in HIV programs treating HIV-infected children and adolescents
between the ages of 0 and 19 years within multiple geographic regions, between 2004 and
2015. We report 3 major findings. First, in HIV-infected children and adolescents, the cumula-
tive incidence of initiating ART within 24 months of enrollment into a program or HIV diag-
nosis was 68%, with a substantial risk for mortality or LTFU before ART initiation (19%),
representing multiple missed opportunities for ART initiation. Second, among children eligi-
ble for ART initiation and followed up, 19% did not initiate treatment within the first 24
months of follow-up. Third, we report a number of inequities in ART access: female sex, chil-
dren <10 years at baseline (and those<1 year in particular), adolescents aged 15–19 years at
baseline (compared to those aged 10–14 years), those becoming eligible during follow-up
(compared to those eligible at baseline), and those living in sub-Saharan Africa compared to
other regions were all less likely to initiate treatment.
The 24-month cumulative incidence for ART initiation was 68%. According to ART eligi-
bility, this was 78.6% among those eligible at baseline and 56.4% among those who became eli-
gible during the study. While these rates are low compared to the UNAIDS target of 90% of
those diagnosed with HIV, they are encouraging compared to previous available studies. For
example, in South Africa, only 34.8% of ART-eligible HIV-infected children initiated ART in
2003 [15]. More recently, in Lesotho, 41.2% of eligible children initiated ART in 2008 [16]. In
Côte d’Ivoire, 55% of eligible children initiated ART in 2009 [17]. Still, the rate of ART initia-
tion among children often lags compared to adults and occurs late, despite progressive guide-
lines stressing immediate treatment initiation for the youngest children regardless of
immunological/clinical status since 2008 [18].
At inclusion in HIV programs, 66.1% of children did not have a date of confirmed HIV
diagnosis, median age was 6 years, and 49.1% were already eligible for ART, highlighting the
late access to ART. Delayed ART initiation is most likely the result of late access to HIV diagno-
sis for HIV-exposed children [19,20]. Difficulties in identifying HIV-exposed infants, limited
capacity to perform routine virological testing in HIV-exposed infants, and long result turn-
around time remain important barriers to timely initiation of treatment [20]. In addition, the
lack of integration of prevention of mother-to-child transmission and pediatric HIV care pro-
grams hampers the delivery of early infant diagnosis [21]. This is mainly related to infrastruc-
ture limitations and time constraints as well as staff shortages [20,22,23]. In older children,
similar structural barriers have been identified [21], along with additional key barriers such as
stigma, lack of knowledge in the adolescent population, and socio-cultural beliefs [24–27].
There are many points at which children may drop out the HIV care cascade. First and fore-
most, linkage to care after HIV diagnosis remains a complex issue [28]. There are many rea-
sons for failing to link a child to care including fear of stigma [29–31], community and
economic factors such as lack of support and finances for transport, missed days of work, and
healthcare worker and infrastructure constraints (e.g., drug stock outs, lack of knowledge
among providers on when to prescribe ART, patients missing appointments, eligible patients
not identified appropriately) [32,33]. Challenges continue even after linkage to care. Although
our results demonstrate the feasibility of large-scale ART rollout for children, 1.9% died and
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20.4% were lost to follow-up before ART initiation. Some of the children who were lost to HIV
care programs may represent undocumented mortality, but they may also be out of care or
may have transferred to other facilities without documentation. Once children were linked to
HIV care, we also observed suboptimal rates of ART initiation among children who became
eligible during follow-up compared to those eligible at enrollment, further undermining the
HIV care cascade.
Direct comparisons with other studies are made difficult by differences in methodology
and definition of outcomes, but our observations underline the many missed opportunities for
ART initiation and the difficulties in keeping children in the pre-ART care cascade. Low reten-
tion among HIV-diagnosed patients waiting to initiate ART, as observed in our study, has also
been previously described in both adult and pediatric populations. Most losses happen
between HIV diagnosis and CD4 staging [34]. Current guidelines no longer require CD4 stag-
ing to start ART, which may contribute to improved retention in care and access to ART.
Weaknesses in the continuity of care services must urgently be addressed in order to
improve ART coverage and survival among HIV-infected children. For perinatally infected
children, other interventions such as family-centered models have also been proposed to
improve linkage to care after diagnosis [35,36]. In older children, use of youth-friendly models
of care may be an important intervention [37–39]. Regardless of the mode and age at infection,
multiple efforts are necessary to reach high uptake of services [40,41]. HIV testing and care
need to be decentralized and brought to communities [42]. There is a need to support families
and healthcare workers to provide HIV services for children [6,43,44]. Finally, the “test and
treat” strategy recommended by WHO in 2015 that advocates starting HIV-infected individu-
als on ART immediately regardless of any eligibility criteria could further prevent these missed
opportunities for ART initiation among HIV-diagnosed children.
We observed disparities in ART initiation between regions, with 24-month cumulative inci-
dence of ART initiation ranging from <75% in sub-Saharan Africa to 78.3% in Asia-Pacific.
This variability could be partly explained by the smaller number of HIV-infected children
treated in Asia-Pacific compared to sub-Saharan Africa, with a larger sample size [6].
We also highlight other inequities in the rollout of ART. Females, children aged<10 years,
and in particular those aged<1 year, along with adolescents aged15 years, were less likely to
initiate treatment. Previous studies have reported on missed opportunities for ART initiation
in both very young children, mostly explained by early mortality before accessing HIV diagno-
sis and subsequent ART initiation, and adolescents, where fear of stigma in the family and
community as well as parental consent requirements are major barriers [25,40,45]. Missed
opportunities for ART initiation in adolescents aged 15–19 years could also be a reflection of
noncompliance with visits. In addition, we observed that children who became eligible during
follow-up were less likely to initiate treatment (asHR: 0.69, 95% CI: 0.68–0.70) compared to
those eligible at enrollment. From a programmatic point of view, this observation strongly
supports the universal “test and treat” strategy [6].
Our results indicate insufficient levels of ART initiation among children who were treat-
ment eligible over the whole study period, but we also observed a gradual improvement in
these rates during more recent time periods. As WHO guidelines began recommending uni-
versal ART in all children and adolescents irrespective of clinical stage or CD4 count in 2015,
we expect the number needed to be treated increased in 2016. While there are still many obsta-
cles that will impede the target of 90% ART coverage, there is an ethical priority to trace all
HIV-exposed children in order to determine HIV status and link them into care if HIV
infected and to treat all children who have already linked to care.
This study has major strengths but also several limitations. First, time to ART initiation
since HIV diagnosis may be incorrectly estimated as data regarding confirmed dates of HIV
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diagnosis were scarce. We used enrollment as a proxy for HIV diagnosis, and therefore time
between HIV diagnosis and ART initiation is likely underestimated in programs that do not
have well-documented HIV diagnosis dates. Furthermore, a left-truncation phenomenon
would mask deaths among HIV-infected children between their HIV diagnosis and inclusion
into HIV programs. This survivor bias undoubtedly leads to further underestimation of the
incidence of missed opportunities for ART initiation among HIV-infected children, and, con-
sequently, the true cumulative incidence of ART initiation among all HIV-infected children is
likely lower than that estimated by these data. Our results illustrate this well: programs where
higher proportions were eligible at diagnosis seemed to do better in terms of ART initiation,
whereas in reality these programs were doing worse as many children were diagnosed too late,
with advanced HIV disease at entry. Imputation of time of diagnosis for those with missing
date of diagnosis could have addressed this limitation in theory, but missing values were too
numerous for this to be done. Because diagnosis is often performed at the same time as inclu-
sion in care, our results reflect as best as possible the situation in routine care.
Second, we observed limitations inherent to data quality: 45% of children had missing data
on variables used to assess ART eligibility. We thus advise caution in the interpretation of our
results, particularly in the context of current universal treatment recommendations. Third,
24-month incidence of ART initiation and missed opportunities for care were derived from
data collected over a 10-year period, during which both national and international guidelines
varied over time. Although we adjusted for evolving ART eligibility criteria during follow-up
in our final model to address this, further analyses would be necessary to better describe the
progress made and treatment gaps on a national level.
Fourth, the outcomes of children lost to follow-up were not well known, and the high pro-
portion of children lost to follow-up (20.4%) includes undocumented mortality, those out of
care, and silent transfers. Both death and being out of care represent poor outcomes from
missed opportunities, but silent transfers may or may not represent ultimate ART initiation.
In the absence of outreach data, it is unclear how these results should be interpreted. To over-
come these limitations, we combined mortality and LTFU as a single outcome (of program-
matic failure) in estimating the cumulative rate of missed opportunities for ART initiation
after enrollment in an HIV care program.
Fifth, HIV programs across and within regions vary. Some programs were specific to chil-
dren once they started therapy, making it likely that those programs only recorded data if chil-
dren initiated ART or were intended to initiate ART but not during the pre-ART period. As a
result, our analysis may further overestimate the overall proportion of HIV-infected children
starting ART as the denominator of all children may have shrunk in these instances. In sensi-
tivity analyses where we excluded such programs from consideration, we observed no signifi-
cant differences in our results, except in overall and regional ART initiation probabilities,
which, as expected, were lower when restricted to sites with ART coverage95%.
The mitigating factor of all these limitations is that the bias in estimating overall cumulative
ART initiation rates goes in one direction, leading to overestimation of the cumulative rate of
the start of treatment. This actually strengthens rather than undermines our conclusions
regarding the continued challenge of universal care and treatment of children and adolescents
living with HIV around the world. In addition, our study is the largest study reported to our
knowledge to document the global pre-ART cascade in pediatrics in 2015, including data from
a large number of diverse programs with significant geographic coverage; this study is a gener-
alizable, authoritative investigation of the state of the worldwide response to the HIV epidemic
in pediatric and adolescent populations living with HIV.
In conclusion, this large global cohort study of children with HIV reported a 24-month
cumulative incidence of ART initiation of 68.2% between 2004 and 2015, and a high 19.3%
Access to antiretroviral therapy among HIV-infected children
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002565 May 4, 2018 16 / 20
cumulative incidence of program attrition prior to treatment start driven by mortality and loss
to programs. Given the limitations to our study data, actual coverage of ART initiation in chil-
dren during the study period is likely to have been lower than the estimates reported. As of 2015,
there remain many obstacles to ART initiation, with substantial risks of loss to programs and
death before ART initiation in the context of incomplete early infant diagnosis, linkage to care,
and treatment initiation even after enrollment in care. In particular, infants<1 year of age and
older adolescents urgently need more effective and targeted interventions to improve their HIV
testing uptake and access to ART in order to facilitate their survival. With expanding adoption of
universal treatment recommendations since 2015, it will be crucial to further monitor progress
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